Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

Aztreonam lysinate (inhalation use)

EU orphan designation number: EU/3/04/204   
Active ingredient: Aztreonam lysinate (inhalation use)
Indication: Treatment of gram negative bacteria lung infections in cystic fibrosis
Sponsor: Gilead Sciences International Ltd.
Flowers Building, Granta Park, Abington, Cambridge CB21 6GT United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Cayston on 21/09/2009 with the number EU/1/09/543

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
28/06/2004 Orphan designation EMEA/OD/006/04 (2004)2312 of 21/06/2004
14/07/2005 Transfer of orphan designation EMEA/OD/006/04/T/01 (2005)2650 of 13/07/2005
04/05/2007 Transfer of orphan designation EMEA/OD/006/04/T/02 (2007)2009 of 02/05/2007